glp 1 agonists for type 2 diabetes GLP1 Receptor vs SGLT2-I in Preventing CKD in T2DM: An Interview – AJKD Blog GLP-1 Receptor Agonists and Research

Although activation of the GLP-1 receptor primarily facilitates weight reduction through appetite suppression, the inclusion of GIP receptor agonism offers supplementary and synergistic advantages, including improved insulin sensitivity and overall metabolic health

GLP-1 acts through its receptors located on immune cells, reducing the production of inflammatory cytokines and infiltration of immune cells in the tissues

These preclinical insights have been validated in large-scale clinical trials.The FLOW trial (n = 3,533) showed that once-weekly subcutaneous administration of semaglutide (1.0 mg) significantly reduced the risk of a renal composite endpointincluding 50% decline in eGFR, renal failure, or cardiovascular deathby 24% in patients with T2DM and chronic kidney disease (CKD) (HR = 0.76, 95% CI: 0.660.88

GLP-1 agonists reduce appetite , which contributes to their role in weight management

E.TolhurstG.HabibA